Loading…
Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients
Comprehensive genomic profiling has been approved for use in patients with advanced solid tumours; however, it is only indicated in advanced solid tumour patients without available standard chemotherapeutic treatment or those who have completed standard treatments in Japan, and there are no availabl...
Saved in:
Published in: | Japanese journal of clinical oncology 2021-12, Vol.51 (12), p.1757-1760 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c385t-6ed10e97c8487751dd71a376dc73349c828715e67e8d7bad0d45537121b7706b3 |
---|---|
cites | cdi_FETCH-LOGICAL-c385t-6ed10e97c8487751dd71a376dc73349c828715e67e8d7bad0d45537121b7706b3 |
container_end_page | 1760 |
container_issue | 12 |
container_start_page | 1757 |
container_title | Japanese journal of clinical oncology |
container_volume | 51 |
creator | Mizuno, Takaaki Yoshida, Tatsuya Sunami, Kuniko Koyama, Takafumi Okita, Natsuko Kubo, Takashi Sudo, Kazuki Shimoi, Tatsunori Ueno, Hideki Saito, Eiko Katanoda, Kota Shibata, Taro Yonemori, Kan Okusaka, Takuji Boku, Narikazu Ohe, Yuichiro Hiroshima, Yukihiko Ueno, Makoto Kuboki, Yasutoshi Doi, Toshihiko Nakamura, Kenichi Kohno, Takashi Yatabe, Yasushi Yamamoto, Noboru |
description | Comprehensive genomic profiling has been approved for use in patients with advanced solid tumours; however, it is only indicated in advanced solid tumour patients without available standard chemotherapeutic treatment or those who have completed standard treatments in Japan, and there are no available data on the clinical feasibility and utility of comprehensive genomic profiling in treatment-naive patients. This multicentre, single-arm, prospective study aims to evaluate the feasibility and utility of the OncoGuide NCC Oncopanel System in treatment-naive patients with six advanced major malignancies: non-small cell lung cancer, breast cancer, gastric cancer, colon cancer, pancreatic cancer and biliary tract cancer (NCCH1908). This study (study cohort) will be compared with the other prospective observational study (control cohort), which enrols patients not receiving comprehensive genomic profiling prior to initial systemic treatment. A total of 200 patients will be enrolled in the study over 21 months. This study has been registered in the UMIN Clinical Trials Registry (www.umin.ac.jp/ctr/) (UMIN000040743).
This study, initiated in June 2020, has been registered in the UMIN Clinical Trials Registry (www.umin.ac.jp/ctr/) (registration number: UMIN000040743). We plan to enrol a total of 200 patients over a period of 21 months. |
doi_str_mv | 10.1093/jjco/hyab159 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2580693784</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2580693784</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-6ed10e97c8487751dd71a376dc73349c828715e67e8d7bad0d45537121b7706b3</originalsourceid><addsrcrecordid>eNpNkc1u1DAURiMEoj-wY428LFLT2nEcO-yqEaVIVYugXUeOfdPxyImH-GakvGyfpQ4zoK78Sffo2Ndfln1i9ILRml9uNiZcrmfdMlG_yY5ZWYmcVwV7-yofZScxbiilQpXyfXbEy6ooas6Os-ffONmZbMeAwQRPujCSu9XqhtVUkbPHn9e_7u8echyd9l--Er2AcQsG3Q6I8W5wRnvyd0wwENhpP2kEgmsgHejoWucdzkQPlky4z6EjJvTbEdYwxMXzBEPonVncXUKGp5RcekcSLp50CS7-OEeEhcMRNPYwYBoRbXd6MGBJDN5ZglMfppFsNboExA_Zu077CB8P52n2eP3tYXWT395__7G6us0NVwLzCiyjUEujSiWlYNZKprmsrJGcl7VRhZJMQCVBWdlqS20pBJesYK2UtGr5aXa296Yd_kwQseldNOC9HiBMsSmEolXNpSoTer5HTfrKOELXpG17Pc4No83SaLM02hwaTfjng3lqe7D_4X8V8hdK_6Jt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2580693784</pqid></control><display><type>article</type><title>Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients</title><source>Oxford Journals Online</source><creator>Mizuno, Takaaki ; Yoshida, Tatsuya ; Sunami, Kuniko ; Koyama, Takafumi ; Okita, Natsuko ; Kubo, Takashi ; Sudo, Kazuki ; Shimoi, Tatsunori ; Ueno, Hideki ; Saito, Eiko ; Katanoda, Kota ; Shibata, Taro ; Yonemori, Kan ; Okusaka, Takuji ; Boku, Narikazu ; Ohe, Yuichiro ; Hiroshima, Yukihiko ; Ueno, Makoto ; Kuboki, Yasutoshi ; Doi, Toshihiko ; Nakamura, Kenichi ; Kohno, Takashi ; Yatabe, Yasushi ; Yamamoto, Noboru</creator><creatorcontrib>Mizuno, Takaaki ; Yoshida, Tatsuya ; Sunami, Kuniko ; Koyama, Takafumi ; Okita, Natsuko ; Kubo, Takashi ; Sudo, Kazuki ; Shimoi, Tatsunori ; Ueno, Hideki ; Saito, Eiko ; Katanoda, Kota ; Shibata, Taro ; Yonemori, Kan ; Okusaka, Takuji ; Boku, Narikazu ; Ohe, Yuichiro ; Hiroshima, Yukihiko ; Ueno, Makoto ; Kuboki, Yasutoshi ; Doi, Toshihiko ; Nakamura, Kenichi ; Kohno, Takashi ; Yatabe, Yasushi ; Yamamoto, Noboru</creatorcontrib><description>Comprehensive genomic profiling has been approved for use in patients with advanced solid tumours; however, it is only indicated in advanced solid tumour patients without available standard chemotherapeutic treatment or those who have completed standard treatments in Japan, and there are no available data on the clinical feasibility and utility of comprehensive genomic profiling in treatment-naive patients. This multicentre, single-arm, prospective study aims to evaluate the feasibility and utility of the OncoGuide NCC Oncopanel System in treatment-naive patients with six advanced major malignancies: non-small cell lung cancer, breast cancer, gastric cancer, colon cancer, pancreatic cancer and biliary tract cancer (NCCH1908). This study (study cohort) will be compared with the other prospective observational study (control cohort), which enrols patients not receiving comprehensive genomic profiling prior to initial systemic treatment. A total of 200 patients will be enrolled in the study over 21 months. This study has been registered in the UMIN Clinical Trials Registry (www.umin.ac.jp/ctr/) (UMIN000040743).
This study, initiated in June 2020, has been registered in the UMIN Clinical Trials Registry (www.umin.ac.jp/ctr/) (registration number: UMIN000040743). We plan to enrol a total of 200 patients over a period of 21 months.</description><identifier>ISSN: 1465-3621</identifier><identifier>EISSN: 1465-3621</identifier><identifier>DOI: 10.1093/jjco/hyab159</identifier><identifier>PMID: 34622931</identifier><language>eng</language><publisher>England</publisher><subject>Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Feasibility Studies ; Genomics ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Multicenter Studies as Topic ; Observational Studies as Topic ; Prospective Studies</subject><ispartof>Japanese journal of clinical oncology, 2021-12, Vol.51 (12), p.1757-1760</ispartof><rights>The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-6ed10e97c8487751dd71a376dc73349c828715e67e8d7bad0d45537121b7706b3</citedby><cites>FETCH-LOGICAL-c385t-6ed10e97c8487751dd71a376dc73349c828715e67e8d7bad0d45537121b7706b3</cites><orcidid>0000-0003-4896-5824 ; 0000-0001-5807-8458 ; 0000-0002-0787-2851 ; 0000-0001-8687-1269</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34622931$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mizuno, Takaaki</creatorcontrib><creatorcontrib>Yoshida, Tatsuya</creatorcontrib><creatorcontrib>Sunami, Kuniko</creatorcontrib><creatorcontrib>Koyama, Takafumi</creatorcontrib><creatorcontrib>Okita, Natsuko</creatorcontrib><creatorcontrib>Kubo, Takashi</creatorcontrib><creatorcontrib>Sudo, Kazuki</creatorcontrib><creatorcontrib>Shimoi, Tatsunori</creatorcontrib><creatorcontrib>Ueno, Hideki</creatorcontrib><creatorcontrib>Saito, Eiko</creatorcontrib><creatorcontrib>Katanoda, Kota</creatorcontrib><creatorcontrib>Shibata, Taro</creatorcontrib><creatorcontrib>Yonemori, Kan</creatorcontrib><creatorcontrib>Okusaka, Takuji</creatorcontrib><creatorcontrib>Boku, Narikazu</creatorcontrib><creatorcontrib>Ohe, Yuichiro</creatorcontrib><creatorcontrib>Hiroshima, Yukihiko</creatorcontrib><creatorcontrib>Ueno, Makoto</creatorcontrib><creatorcontrib>Kuboki, Yasutoshi</creatorcontrib><creatorcontrib>Doi, Toshihiko</creatorcontrib><creatorcontrib>Nakamura, Kenichi</creatorcontrib><creatorcontrib>Kohno, Takashi</creatorcontrib><creatorcontrib>Yatabe, Yasushi</creatorcontrib><creatorcontrib>Yamamoto, Noboru</creatorcontrib><title>Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients</title><title>Japanese journal of clinical oncology</title><addtitle>Jpn J Clin Oncol</addtitle><description>Comprehensive genomic profiling has been approved for use in patients with advanced solid tumours; however, it is only indicated in advanced solid tumour patients without available standard chemotherapeutic treatment or those who have completed standard treatments in Japan, and there are no available data on the clinical feasibility and utility of comprehensive genomic profiling in treatment-naive patients. This multicentre, single-arm, prospective study aims to evaluate the feasibility and utility of the OncoGuide NCC Oncopanel System in treatment-naive patients with six advanced major malignancies: non-small cell lung cancer, breast cancer, gastric cancer, colon cancer, pancreatic cancer and biliary tract cancer (NCCH1908). This study (study cohort) will be compared with the other prospective observational study (control cohort), which enrols patients not receiving comprehensive genomic profiling prior to initial systemic treatment. A total of 200 patients will be enrolled in the study over 21 months. This study has been registered in the UMIN Clinical Trials Registry (www.umin.ac.jp/ctr/) (UMIN000040743).
This study, initiated in June 2020, has been registered in the UMIN Clinical Trials Registry (www.umin.ac.jp/ctr/) (registration number: UMIN000040743). We plan to enrol a total of 200 patients over a period of 21 months.</description><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Feasibility Studies</subject><subject>Genomics</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Multicenter Studies as Topic</subject><subject>Observational Studies as Topic</subject><subject>Prospective Studies</subject><issn>1465-3621</issn><issn>1465-3621</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpNkc1u1DAURiMEoj-wY428LFLT2nEcO-yqEaVIVYugXUeOfdPxyImH-GakvGyfpQ4zoK78Sffo2Ndfln1i9ILRml9uNiZcrmfdMlG_yY5ZWYmcVwV7-yofZScxbiilQpXyfXbEy6ooas6Os-ffONmZbMeAwQRPujCSu9XqhtVUkbPHn9e_7u8echyd9l--Er2AcQsG3Q6I8W5wRnvyd0wwENhpP2kEgmsgHejoWucdzkQPlky4z6EjJvTbEdYwxMXzBEPonVncXUKGp5RcekcSLp50CS7-OEeEhcMRNPYwYBoRbXd6MGBJDN5ZglMfppFsNboExA_Zu077CB8P52n2eP3tYXWT395__7G6us0NVwLzCiyjUEujSiWlYNZKprmsrJGcl7VRhZJMQCVBWdlqS20pBJesYK2UtGr5aXa296Yd_kwQseldNOC9HiBMsSmEolXNpSoTer5HTfrKOELXpG17Pc4No83SaLM02hwaTfjng3lqe7D_4X8V8hdK_6Jt</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Mizuno, Takaaki</creator><creator>Yoshida, Tatsuya</creator><creator>Sunami, Kuniko</creator><creator>Koyama, Takafumi</creator><creator>Okita, Natsuko</creator><creator>Kubo, Takashi</creator><creator>Sudo, Kazuki</creator><creator>Shimoi, Tatsunori</creator><creator>Ueno, Hideki</creator><creator>Saito, Eiko</creator><creator>Katanoda, Kota</creator><creator>Shibata, Taro</creator><creator>Yonemori, Kan</creator><creator>Okusaka, Takuji</creator><creator>Boku, Narikazu</creator><creator>Ohe, Yuichiro</creator><creator>Hiroshima, Yukihiko</creator><creator>Ueno, Makoto</creator><creator>Kuboki, Yasutoshi</creator><creator>Doi, Toshihiko</creator><creator>Nakamura, Kenichi</creator><creator>Kohno, Takashi</creator><creator>Yatabe, Yasushi</creator><creator>Yamamoto, Noboru</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4896-5824</orcidid><orcidid>https://orcid.org/0000-0001-5807-8458</orcidid><orcidid>https://orcid.org/0000-0002-0787-2851</orcidid><orcidid>https://orcid.org/0000-0001-8687-1269</orcidid></search><sort><creationdate>20211201</creationdate><title>Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients</title><author>Mizuno, Takaaki ; Yoshida, Tatsuya ; Sunami, Kuniko ; Koyama, Takafumi ; Okita, Natsuko ; Kubo, Takashi ; Sudo, Kazuki ; Shimoi, Tatsunori ; Ueno, Hideki ; Saito, Eiko ; Katanoda, Kota ; Shibata, Taro ; Yonemori, Kan ; Okusaka, Takuji ; Boku, Narikazu ; Ohe, Yuichiro ; Hiroshima, Yukihiko ; Ueno, Makoto ; Kuboki, Yasutoshi ; Doi, Toshihiko ; Nakamura, Kenichi ; Kohno, Takashi ; Yatabe, Yasushi ; Yamamoto, Noboru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-6ed10e97c8487751dd71a376dc73349c828715e67e8d7bad0d45537121b7706b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Feasibility Studies</topic><topic>Genomics</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Multicenter Studies as Topic</topic><topic>Observational Studies as Topic</topic><topic>Prospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mizuno, Takaaki</creatorcontrib><creatorcontrib>Yoshida, Tatsuya</creatorcontrib><creatorcontrib>Sunami, Kuniko</creatorcontrib><creatorcontrib>Koyama, Takafumi</creatorcontrib><creatorcontrib>Okita, Natsuko</creatorcontrib><creatorcontrib>Kubo, Takashi</creatorcontrib><creatorcontrib>Sudo, Kazuki</creatorcontrib><creatorcontrib>Shimoi, Tatsunori</creatorcontrib><creatorcontrib>Ueno, Hideki</creatorcontrib><creatorcontrib>Saito, Eiko</creatorcontrib><creatorcontrib>Katanoda, Kota</creatorcontrib><creatorcontrib>Shibata, Taro</creatorcontrib><creatorcontrib>Yonemori, Kan</creatorcontrib><creatorcontrib>Okusaka, Takuji</creatorcontrib><creatorcontrib>Boku, Narikazu</creatorcontrib><creatorcontrib>Ohe, Yuichiro</creatorcontrib><creatorcontrib>Hiroshima, Yukihiko</creatorcontrib><creatorcontrib>Ueno, Makoto</creatorcontrib><creatorcontrib>Kuboki, Yasutoshi</creatorcontrib><creatorcontrib>Doi, Toshihiko</creatorcontrib><creatorcontrib>Nakamura, Kenichi</creatorcontrib><creatorcontrib>Kohno, Takashi</creatorcontrib><creatorcontrib>Yatabe, Yasushi</creatorcontrib><creatorcontrib>Yamamoto, Noboru</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mizuno, Takaaki</au><au>Yoshida, Tatsuya</au><au>Sunami, Kuniko</au><au>Koyama, Takafumi</au><au>Okita, Natsuko</au><au>Kubo, Takashi</au><au>Sudo, Kazuki</au><au>Shimoi, Tatsunori</au><au>Ueno, Hideki</au><au>Saito, Eiko</au><au>Katanoda, Kota</au><au>Shibata, Taro</au><au>Yonemori, Kan</au><au>Okusaka, Takuji</au><au>Boku, Narikazu</au><au>Ohe, Yuichiro</au><au>Hiroshima, Yukihiko</au><au>Ueno, Makoto</au><au>Kuboki, Yasutoshi</au><au>Doi, Toshihiko</au><au>Nakamura, Kenichi</au><au>Kohno, Takashi</au><au>Yatabe, Yasushi</au><au>Yamamoto, Noboru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients</atitle><jtitle>Japanese journal of clinical oncology</jtitle><addtitle>Jpn J Clin Oncol</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>51</volume><issue>12</issue><spage>1757</spage><epage>1760</epage><pages>1757-1760</pages><issn>1465-3621</issn><eissn>1465-3621</eissn><abstract>Comprehensive genomic profiling has been approved for use in patients with advanced solid tumours; however, it is only indicated in advanced solid tumour patients without available standard chemotherapeutic treatment or those who have completed standard treatments in Japan, and there are no available data on the clinical feasibility and utility of comprehensive genomic profiling in treatment-naive patients. This multicentre, single-arm, prospective study aims to evaluate the feasibility and utility of the OncoGuide NCC Oncopanel System in treatment-naive patients with six advanced major malignancies: non-small cell lung cancer, breast cancer, gastric cancer, colon cancer, pancreatic cancer and biliary tract cancer (NCCH1908). This study (study cohort) will be compared with the other prospective observational study (control cohort), which enrols patients not receiving comprehensive genomic profiling prior to initial systemic treatment. A total of 200 patients will be enrolled in the study over 21 months. This study has been registered in the UMIN Clinical Trials Registry (www.umin.ac.jp/ctr/) (UMIN000040743).
This study, initiated in June 2020, has been registered in the UMIN Clinical Trials Registry (www.umin.ac.jp/ctr/) (registration number: UMIN000040743). We plan to enrol a total of 200 patients over a period of 21 months.</abstract><cop>England</cop><pmid>34622931</pmid><doi>10.1093/jjco/hyab159</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-4896-5824</orcidid><orcidid>https://orcid.org/0000-0001-5807-8458</orcidid><orcidid>https://orcid.org/0000-0002-0787-2851</orcidid><orcidid>https://orcid.org/0000-0001-8687-1269</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1465-3621 |
ispartof | Japanese journal of clinical oncology, 2021-12, Vol.51 (12), p.1757-1760 |
issn | 1465-3621 1465-3621 |
language | eng |
recordid | cdi_proquest_miscellaneous_2580693784 |
source | Oxford Journals Online |
subjects | Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Feasibility Studies Genomics Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Multicenter Studies as Topic Observational Studies as Topic Prospective Studies |
title | Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T10%3A17%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Study%20protocol%20for%20NCCH1908%20(UPFRONT-trial):%20a%20prospective%20clinical%20trial%20to%20evaluate%20the%20feasibility%20and%20utility%20of%20comprehensive%20genomic%20profiling%20prior%20to%20the%20initial%20systemic%20treatment%20in%20advanced%20solid%20tumour%20patients&rft.jtitle=Japanese%20journal%20of%20clinical%20oncology&rft.au=Mizuno,%20Takaaki&rft.date=2021-12-01&rft.volume=51&rft.issue=12&rft.spage=1757&rft.epage=1760&rft.pages=1757-1760&rft.issn=1465-3621&rft.eissn=1465-3621&rft_id=info:doi/10.1093/jjco/hyab159&rft_dat=%3Cproquest_cross%3E2580693784%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c385t-6ed10e97c8487751dd71a376dc73349c828715e67e8d7bad0d45537121b7706b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2580693784&rft_id=info:pmid/34622931&rfr_iscdi=true |